Thermo Fisher Scientific Inc. TMO
NYSE
| 09/26/2026 | 06/27/2026 | 03/28/2026 | 12/31/2025 | 09/27/2025 | |
|---|---|---|---|---|---|
| Net Income | 7.07B | 6.97B | 6.85B | 6.70B | 6.57B |
| Total Depreciation and Amortization | 3.11B | 2.94B | 2.81B | 2.78B | 2.79B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 279.00M | 298.00M | 125.00M | 142.00M | -52.00M |
| Change in Net Operating Assets | -1.13B | -1.19B | -1.50B | -1.81B | -1.66B |
| Cash from Operations | 9.32B | 9.01B | 8.29B | 7.82B | 7.65B |
| Capital Expenditure | -1.73B | -1.70B | -1.54B | -1.53B | -1.54B |
| Sale of Property, Plant, and Equipment | 41.00M | 44.00M | 41.00M | 44.00M | 34.00M |
| Cash Acquisitions | -8.88B | -12.91B | -12.91B | -4.04B | -4.04B |
| Divestitures | 1.02B | -- | -- | -- | -- |
| Other Investing Activities | 1.56B | 2.53B | 1.93B | 1.47B | 625.00M |
| Cash from Investing | -7.98B | -12.03B | -12.48B | -4.05B | -4.92B |
| Total Debt Issued | 10.55B | 11.64B | 11.64B | 8.85B | 3.94B |
| Total Debt Repaid | -4.19B | -3.68B | -4.08B | -3.51B | -4.72B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -4.04B | -5.00B | -4.00B | -3.00B | -3.96B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -673.00M | -662.00M | -649.00M | -636.00M | -623.00M |
| Other Financing Activities | 342.00M | 120.00M | 85.00M | 90.00M | -18.00M |
| Cash from Financing | 1.99B | 2.42B | 3.00B | 1.80B | -5.39B |
| Foreign Exchange rate Adjustments | 158.00M | 95.00M | 308.00M | 267.00M | 0.00 |
| Miscellaneous Cash Flow Adjustments | -1.00M | -2.00M | -2.00M | 0.00 | -1.00M |
| Net Change in Cash | 3.48B | -507.00M | -892.00M | 5.84B | -2.66B |